RxDoctor Payments Data

Tena Murphy, MD

Cardiovascular Disease · Little Rock, ARNPI 1821009341

Payments from drug & device makers

$1,304in general payments, 2019–2025

Across 96 payments — averaging $13.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$736
  • United Therapeutics Corporation$95
  • Sanofi-aventis U.S. LLC$93
  • E.r. Squibb & Sons, L.L.C.$66
  • Boehringer Ingelheim$66
  • Boston Scientific$50
  • plus $199 from 9 others

What the payments were for

  • Food & beverage$1,304100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,304 in reported general payments places this provider in the 25th percentile of 130 cardiovascular disease providers in Arkansas.

See all cardiovascular disease providers in Arkansas

Medicare billing

Part B allowed, 2024
$149,023
Medicare patients
995
Services billed
2,308

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban579$462,340
EntrestoSacubitril/Valsartan193$176,654
XareltoRivaroxaban224$162,719
JardianceEmpagliflozin45$51,715
MultaqDronedarone Hcl19$26,339
FarxigaDapagliflozin Propanediol21$13,133
Metoprolol Succinate706$9,888
Ranolazine ErRanolazine55$4,753
Nisoldipine13$4,608
Atorvastatin Calcium457$3,833
Losartan Potassium400$3,733
Hydralazine Hcl315$2,786
Ezetimibe105$2,563
Diltiazem 24hr Er (Cd)Diltiazem Hcl96$2,157
Verapamil ErVerapamil Hcl105$1,961

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$12$462,340579 claims
NovartisEntresto$736$176,654193 claims
Johnson & JohnsonXarelto$33$162,719224 claims
Boehringer IngelheimJardiance$66$51,71545 claims
Sanofi-aventis U.S. LLCMultaq$93$26,33919 claims
AstraZenecaFarxiga$31$13,13321 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 130 cardiovascular disease providers in Arkansas.

Other cardiovascular disease in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →